Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126610 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL4968784 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL2832489 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL2829406 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL1936442 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL15345824 | 0.86 | MEN1 (0.48) | DUTALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL15750871 | 0.85 | DUT (0.32) | DUT | |
| SCHEMBL571057 | 0.85 | DUT (0.39) | DUT | |
| Ammonia Solution, Strong SCHEMBL9187414 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL334934 | 0.83 | DUT (0.38) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534646-B | Preparation method of procyanidine B2 | 朗华生物科学(深圳)有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-118239787-A | Ground silicon nitride ceramic chip | 江苏富乐华功率半导体研究院有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-115093657-B | Wear-resistant PVC material and application thereof | 广东亮丰达实业有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117658967-A | Preparation method of flavan-3, 4-diol derivative | 朗华生物科学(深圳)有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-117534646-A | Preparation method of procyanidine B2 | 朗华生物科学(深圳)有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-116813641-A | Preparation method of everolimus | 杭州华东医药集团康润制药有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-114853831-B | Antitumor compound and preparation method and application thereof | 四川瑞泽健科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-113801303-B | Method and device for preparing polylactic acid | 北京工商大学 | 2023-07-18 | — | — | CN | claimed |
| CN-115093657-A | Wear-resistant PVC material and application thereof | 广东亮丰达实业有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114853831-A | Antitumor compound and preparation method and application thereof | 四川瑞泽健科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| EP-3539968-B1 | NOVEL TRITYL PROTECTING AGENT | SEKISUI MEDICAL CO LTD (JP) | 2021-07-14 | — | — | EP | claimed |
| US-10981940-B2 | Trityl protecting agent | SEKISUl MEDICAL CO., LTD. (JP) | 2021-04-20 | — | — | US | claimed |
| CN-108795289-B | Nano titanium surface loaded Si, Cu-TiO 2Preparation method of antibacterial bioactive film layer | 温州医科大学附属口腔医院 | 2020-07-17 | — | — | CN | claimed |
| CN-106153755-B | Analysis and detection method of 2- (tert-butyl dimethyl silicon alkyloxy) ethanol | 山东新时代药业有限公司 | 2020-02-14 | — | — | CN | claimed |
| US-20190308997-A1 | NOVEL TRITYL PROTECTING AGENT | SEKISUI MEDICAL CO., LTD. (JP) | 2019-10-10 | — | — | US | claimed |
| EP-3539968-A1 | NOVEL TRITYL PROTECTING AGENT | Sekisui Medical Co., Ltd. (JP) | 2019-09-18 | — | — | EP | claimed |
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | claimed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | claimed |
| EP-3166950-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | Cipla Limited (IN) | 2017-05-17 | — | — | EP | claimed |
| WO-2016020664-A1 | PROCESS FOR THE SYNTHESIS OF EVEROLIMUS AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2016-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981940-B2 | Trityl protecting agent | POT1, TXNL1, TXLNA | DUT 4663/4885ALDH1A1 1839/4885TSHR 482/4885 |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | MTOR, RICTOR, RPTOR | DUT 1092/4885ALDH1A1 2765/4885TSHR 4306/4885 |
| US-20190308997-A1 | NOVEL TRITYL PROTECTING AGENT | POT1, TXNL1, TXLNA | DUT 4627/4885ALDH1A1 1482/4885TSHR 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.